Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Capital Leases (2019 - 2022)

Historic Capital Leases for Rhythm Pharmaceuticals (RYTM) over the last 4 years, with Q1 2022 value amounting to $1.8 million.

  • Rhythm Pharmaceuticals' Capital Leases fell 2597.67% to $1.8 million in Q1 2022 from the same period last year, while for Mar 2022 it was $1.8 million, marking a year-over-year decrease of 2597.67%. This contributed to the annual value of $1.9 million for FY2021, which is N/A changed from last year.
  • According to the latest figures from Q1 2022, Rhythm Pharmaceuticals' Capital Leases is $1.8 million, which was down 2597.67% from $1.9 million recorded in Q4 2021.
  • Rhythm Pharmaceuticals' 5-year Capital Leases high stood at $3.4 million for Q1 2019, and its period low was $1.8 million during Q1 2022.
  • Moreover, its 4-year median value for Capital Leases was $2.7 million (2020), whereas its average is $2.6 million.
  • In the last 5 years, Rhythm Pharmaceuticals' Capital Leases plummeted by 1510.06% in 2020 and then crashed by 2597.67% in 2022.
  • Quarter analysis of 4 years shows Rhythm Pharmaceuticals' Capital Leases stood at $3.1 million in 2019, then decreased by 12.77% to $2.7 million in 2020, then fell by 27.75% to $1.9 million in 2021, then decreased by 8.43% to $1.8 million in 2022.
  • Its Capital Leases was $1.8 million in Q1 2022, compared to $1.9 million in Q4 2021 and $2.1 million in Q3 2021.